The global CRISPR-based gene editing market size was valued at USD 3.58 billion in 2023 and is expected to expand significantly, reaching USD 9.14 billion by 2030. This marks a compound annual growth rate (CAGR) of 14.73% from 2024 to 2030. The robust growth of this market is primarily fueled by several crucial factors, including the increasing incidence of genetic disorders, continual advancements in gene editing research and technology, favorable governmental policies and regulatory frameworks, and a surge in investments from public and private sectors in the field of biotechnology.

According to statistics provided by the World Health Organization (WHO), more than 400 million individuals worldwide are affected by genetic disorders. Among the most prominent of these conditions are cystic fibrosis, sickle cell disease, and muscular dystrophy, all of which pose significant challenges to healthcare systems due to their chronic nature and limited treatment options. In this context, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has emerged as a groundbreaking solution that enables highly accurate and efficient gene editing. By allowing targeted modifications at the DNA level, CRISPR holds promise for correcting genetic mutations and facilitating the development of novel therapies that could revolutionize how these diseases are treated.

As the global burden of genetic diseases continues to increase, there is a mounting demand for advanced therapeutic interventions. This escalating need positions CRISPR as a central focus within modern biomedical research, reinforcing its potential as a transformative technology in next-generation medicine and gene therapy.

Key Market Trends & Insights:

• North America held the dominant position in the global CRISPR-based gene editing market in 2023, accounting for the largest revenue share of 41.60%. The U.S. market, in particular, is projected to exhibit substantial growth throughout the forecast period, supported by its advanced research infrastructure, strong presence of biotechnology firms, and ongoing clinical development activities.
• In contrast, the Asia Pacific region is anticipated to emerge as the fastest-growing market, registering a notable CAGR of 16.86% between 2024 and 2030. This rapid growth is attributed to expanding research capabilities, growing investments in genetic engineering, and rising awareness of personalized medicine in countries like China, Japan, and India.
• From a product perspective, the products segment, which comprises CRISPR kits and reagents, CRISPR libraries, and associated laboratory tools, dominated the market in 2023 by capturing a revenue share of 73.96%. These tools are essential for both academic and commercial research applications and are widely adopted across laboratories worldwide. Meanwhile, the services segment is projected to record the fastest CAGR of 15.76% over the forecast period.
• In terms of application, the biomedical segment led the market with the largest revenue share of 81.83% in 2023 and is expected to maintain its dominance through 2030. This segment's rapid growth is propelled by the increasing utilization of CRISPR in therapeutic research, diagnostics, and drug development, particularly for genetically inherited diseases and cancer. The biomedical segment is also forecasted to grow at the fastest CAGR of 15.09% during the forecast period.
• Based on end-use, pharmaceutical and biotechnology companies represented the leading market segment in 2023, with a revenue share of 46.31%. These companies are leveraging CRISPR to enhance drug discovery pipelines and develop gene-based therapies. However, the contract research organizations (CROs) segment is anticipated to witness the fastest growth rate, with a CAGR of 17.12% from 2024 to 2030.

Order a free sample PDF of the CRISPR-based Gene Editing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2023 Market Size: USD 3.58 Billion
• 2030 Projected Market Size: USD 9.14 Billion
• CAGR (2024-2030): 14.73%
• North America: Largest market in 2023
• Asia Pacific: Fastest growing market

Key Players

The following are the leading companies in the CRISPR-based gene editing market. These companies collectively hold the largest market share and dictate industry trends.

• Revvity, Inc.
• Danaher
• GenScript
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Tocris Bioscience
• OriGene Technologies, Inc.
• Bio-Rad Laboratories
• Bio-Techne
• New England Biolabs, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global CRISPR-based gene editing market is poised for significant growth, driven by the increasing prevalence of genetic disorders, technological advancements, supportive government initiatives, and growing investments in biotechnology. With strong dominance in North America and rapid growth in Asia Pacific, CRISPR is emerging as a transformative tool in biomedical research and therapeutics. As demand for precise and effective treatments rises, CRISPR technology continues to play a pivotal role in revolutionizing the future of genetic medicine.